Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(10)
DRUG(3)
BIOLOGICAL(1)
hA20-humanized anti-CD20 antibody
5 trials
phase_1_2
gilead-sciences
milatuzumab
3 trials
phase_1phase_1_2
gilead-sciences
Veltuzumab and 90Y-Epratuzumab Tetraxetan
1 trial
phase_1_2
gilead-sciences
IMMU-107 (hPAM4)
1 trial
phase_1_2
gilead-sciences
IMMU-114
1 trial
phase_1
gilead-sciences
90Y-epratuzumab tetraxetan
1 trial
phase_1_2
gilead-sciences
90Y-hPAM4
1 trial
phase_1_2
gilead-sciences
Gemcitabine
1 trial
phase_3
gilead-sciences
8 unique interventions3 categories

Analytics

Trial Phases

Phase 111
Phase 29
Phase 31

Trial Status

Completed7
Terminated4
Other1

Role Distribution

Other Roles12

Activity Timeline

Clinical Trials (12)

NCT01663766Phase 1Terminated
Phase I Study of Milatuzumab for Graft Versus Host Disease
Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)Chronic Myelogenous Leukemia (CML)+4 more
StudychairStart date: 2013-12-01
NCT01956812Phase 3Terminated
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Metastatic Pancreatic CancerPancreatic Cancer
StudychairStart date: 2013-12-01
NCT01101581Phase 1/2Withdrawn
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Aggressive NHLDiffuse Large B-cell LymphomaNHL+1 more
StudychairStart date: 2010-05-01
NCT00421525Phase 1/2Completed
Phase I/II Study of hLL1 in Multiple Myeloma
Multiple MyelomaMyeloma, Plasma-CellPLASMACYTOMA
StudychairStart date: 2007-01-01
NCT00285428Phase 1/2Completed
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Studychair
NCT00546793Phase 1/2Completed
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
CLLLeukemia, B-Cell, ChronicLeukemia, Lymphocytic, Chronic+15 more
Studydirector
NCT00547066Phase 1/2Terminated
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Autoimmune Thrombocytopenic PurpuraPurpura, Thrombocytopenic, AutoimmunePurpura, Thrombocytopenic, Idiopathic
Studychair
NCT00596804Phase 1/2Completed
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Lymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-HistiocyticNon-Hodgkin's Lymphoma
Studychair
NCT00597129Phase 1/2Completed
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
Pancreatic Cancer
Studychair
NCT00603668Phase 1/2Completed
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Chronic Lymphocytic Lymphoma
Studychair

Showing 10 of 12 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphoma, Follicular+5 more
Similarity Score8%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMarginal Zone Lymphoma+1 more
Similarity Score4%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Mantle-Cell+1 more
Similarity Score4%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Cancer of PancreasMetastatic Pancreatic CancerMultiple Myeloma
Similarity Score3%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLymphoma, Low-GradeMultiple Myeloma
Similarity Score3%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Myelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphoma, Large B-Cell, Diffuse
Similarity Score3%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score3%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Similarity Score3%

Project Leader

Ono Pharmaceutical Co., Ltd.

Related
47 trials

Shared therapeutic areas:

Metastatic Pancreatic CancerMyelodysplastic SyndromesLymphoma, Non-Hodgkin
Similarity Score3%

David Avigan, MD

Beth Israel Deaconess Medical Center

Related
17 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (12)

Showing 12 of 12 trials

NCT01663766Phase 1StudyChair

Phase I Study of Milatuzumab for Graft Versus Host Disease

Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)Chronic Myelogenous Leukemia (CML)+4 more
Terminated
NCT01956812Phase 3StudyChair

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic CancerPancreatic Cancer
Terminated
NCT01101581Phase 1/2StudyChair

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Aggressive NHLDiffuse Large B-cell LymphomaNHL+1 more
Withdrawn
NCT00421525Phase 1/2StudyChair

Phase I/II Study of hLL1 in Multiple Myeloma

Multiple MyelomaMyeloma, Plasma-CellPLASMACYTOMA
Completed
NCT00285428Phase 1/2StudyChair

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Completed
NCT00546793Phase 1/2StudyDirector

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

CLLLeukemia, B-Cell, ChronicLeukemia, Lymphocytic, Chronic+15 more
Completed
NCT00547066Phase 1/2StudyChair

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Autoimmune Thrombocytopenic PurpuraPurpura, Thrombocytopenic, AutoimmunePurpura, Thrombocytopenic, Idiopathic
Terminated
NCT00596804Phase 1/2StudyChair

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Lymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-HistiocyticNon-Hodgkin's Lymphoma
Completed
NCT00597129Phase 1/2StudyChair

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Pancreatic Cancer
Completed
NCT00603668Phase 1/2StudyChair

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Chronic Lymphocytic Lymphoma
Completed
NCT00603863Phase 1/2StudyChair

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Pancreatic Cancer
Completed
NCT01728207Phase 1StudyChair

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Chronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell Lymphoma+3 more
Terminated

All 12 trials loaded